摘要:
The present invention relates to a composition for improving the stability of bacteriophage originated lysin proteins greatly even when the composition contains the bacteriophage originated lysin proteins at a high concentration. More precisely, the present invention relates to a method and a composition for improving significantly the stability of SAL-1 or LysK, the bacteriophage originated lysin protein, included at a high concentration in the composition.
摘要:
The present invention relates to a composition comprising STP-1, a bacteriophage isolated from nature, capable of infecting Salmonella Typhimurium so as to kill the same as an active ingredient, and a method for preventing and treating Salmonella Typhimurium infection using the said composition. According to the present invention, the bacteriophage STP-1, an active ingredient of the composition, has a killing activity against Salmonella Typhimurium and has the genome represented by SEQ. ID. NO: 1.
摘要翻译:本发明涉及一种组合物,其包含STP-1,从自然界分离的能够感染鼠伤寒沙门氏菌以杀死与活性成分相同的噬菌体,以及使用所述组合物预防和治疗鼠伤寒沙门氏菌感染的方法。 根据本发明,组合物的活性成分的噬菌体STP-1对鼠伤寒沙门氏菌具有杀伤活性,并具有SEQ ID NO: ID。 NO:1。
摘要:
The present invention relates to a composition comprising STP-1, a bacteriophage isolated from nature, capable of infecting Salmonella Typhimurium so as to kill the same as an active ingredient, and a method for preventing and treating Salmonella Typhimurium infection using the said composition. According to the present invention, the bacteriophage STP-1, an active ingredient of the composition, has a killing activity against Salmonella Typhimurium and has the genome represented by SEQ. ID. NO: 1.
摘要翻译:本发明涉及一种组合物,其包含STP-1,从自然界分离的能够感染鼠伤寒沙门氏菌以杀死与活性成分相同的噬菌体,以及使用所述组合物预防和治疗鼠伤寒沙门氏菌感染的方法。 根据本发明,组合物的活性成分的噬菌体STP-1对鼠伤寒沙门氏菌具有杀伤活性,并具有SEQ ID NO: ID。 NO:1。
摘要:
The present invention relates to a composition for improving the stability of bacteriophage originated lysin proteins greatly even when the composition contains the bacteriophage originated lysin proteins at a high concentration. More precisely, the present invention relates to a method and a composition for improving significantly the stability of SAL-1 or LysK, the bacteriophage originated lysin protein, included at a high concentration in the composition.
摘要:
The present invention relates to a magnetic resonance imaging (MRI) contrast agent coated with carboxylated mannan, particularly a carboxylated mannan coated superparamagnetic MRI contrast agent specifically targeting antigen presenting cells and having excellent in vivo stability, and a method for producing the same. The MRI contrast agent coated with carboxylated mannan of the present invention can provide excellent in vivo stability and biocompatibility owing to its high surface negative charge, and can be introduced specifically into antigen presenting cells owing to mannose of mannan, so as to visualize the antigen presenting cells and the tissue containing the antigen presenting cells in MRI.
摘要:
The present invention relates to a bacteriophage having bactericidal activity against Actinobacillus pleuropneumoniae. Bacteriophage PA1Φ can infect Actinobacillus pleuropneumoniae and kill the same bacteria and is characterized by the genome of 34,553 by represented by SEQ ID NO: 1.
摘要翻译:本发明涉及对放线杆菌胸膜肺炎放线芽孢杆菌具有杀菌活性的噬菌体。 噬菌体PA1Φ可以感染放线杆菌胸膜肺炎放线芽孢杆菌并杀死相同的细菌,其特征在于由SEQ ID NO:1表示的34,553基因组。
摘要:
The present invention relates to a bacteriophage having bactericidal activity against Actinobacillus pleuropneumoniae. Bacteriophage PA1Φ can infect Actinobacillus pleuropneumoniae and kill the same bacteria and is characterized by the genome of 34,553 by represented by SEQ ID NO: 1.
摘要翻译:本发明涉及对放线杆菌胸膜肺炎放线芽孢杆菌具有杀菌活性的噬菌体。 噬菌体PA1Φ可以感染放线杆菌胸膜肺炎放线芽孢杆菌并杀死相同的细菌,其特征在于由SEQ ID NO:1表示的34,553基因组。
摘要:
The present invention relates to a magnetic resonance imaging (MRI) contrast agent coated with carboxylated mannan, particularly a carboxylated mannan coated superparamagnetic MRI contrast agent specifically targeting antigen presenting cells and having excellent in vivo stability, and a method for producing the same. The MRI contrast agent coated with carboxylated mannan of the present invention can provide excellent in vivo stability and biocompatibility owing to its high surface negative charge, and can be introduced specifically into antigen presenting cells owing to mannose of mannan, so as to visualize the antigen presenting cells and the tissue containing the antigen presenting cells in MRI.